Neetal Nevrekar, MD

CRS:

BJMC

Role:

Clinical

Position:

Research Clinician

Email:

drneetal24@gmail.com

Dr. Neetal Nevrekar is a research clinician at BJMC-CRS in Pune, India, where she has worked since June 2010. She is experienced in the field of clinical research on HIV, and works on various IMPAACT and ACTG Network research protocols. She worked on research protocols A5207, A5253, and A5225 as a research officer. Presently working on protocols 1077BF and 1077FF (PROMISE), A5282, A5288, and P1078 as a study clinician. 

She screens and enrolls research participants, is involved in developing the source documents for research protocols, and in completing clinical record forms. She is also responsible for adverse event reporting to RSC/DAIDS and for communications with Clinical Managing Committee (CMC) of the respective protocols eith regard to clinical management issues, toxicities, change of study drugs.

Dr. Nevrekar conducts training programs at the site for research staff, counselors and clinical personnel. She has received training in Good Clinical Practices and also completed web based GCP, HSP training. She was a member of Women’s Health Inter-network Scientific Committee (WHISC) for the IMPAACT and ACTG Network.

Dr. Nevrekar received an undergraduate degree from Grant Medical Institute, Mumbai, and a Doctor of Medicine in Obstetrics and Gynaecology from Grant Medical Institute and Bombay Hospital Research Centre. She worked as a senior medical officer at Bombay Hospital Research Centre for four years. Subsequently she was a consultant in Obstetrics and Gynaecology for six years.

  • “Vaginal delivery in a case of Pregnancy with Cervical Fibroid” - Journal of F.I.G.O, vol.49 no.2, page 77 dated April 1999.
  • “A Quadruplet Pregnancy” - Journal of F.I.G.O, vol.57 no.5, page 439-441 dated Sept-Oct. 2007.

Categories

Leadership Committees
CRS
Roles

Clinical Trials

ACTIV-2/A5401: Adaptive Platform Treatment for Outpatients...

Rationale: There is an urgent need for a platform to rapidly evaluate therapies in the outpatient setting, to prevent disease...

Read More

A5290, A Randomized, Phase 2b Study of a Double-Dose...

Rifampin (RIF), the cornerstone of TB treatment, has very problematic drug-drug interactions with PIs. The use of relatively...

Read More

The Pharmacokinetics, Safety and Acceptability of New...

PK, safety and acceptability data and practical guidance on the optimal dosing of new more child-friendly formulations of...

Read More

A5207, Maintaining Options for Mothers Study (MOMS): A Phase...

A major disadvantage of giving SD NVP is the potential for maternal development of NVP resistance and additional resistance to...

Read More

A5361s: Pitavastatin to REduce Physical Function Impairment...

A5361s is a prospective study to determine the effects of pitavastatin on physical function. The study will enroll participants...

Read More